Advertisement.

REDIF Projected Dividend Yield

Redhill Biopharma Ltd, Ramat Gan ( OTCBB : REDIF )

RedHill Biopharma is a biopharmaceutical company, primarily focused on proprietary drugs for gastrointestinal (GI) diseases. The ongoing development programs of Co.'s seven therapeutic candidates, most in late-stage clinical development, include TALICIA®, RHB-104, RHB-204, BEKINDA®, RHB-106, YELIVA® and RHB-107 and related research and development programs. TALICIA® is an investigational new drug for the eradication of H. pylori bacterial infection in the GI tract. RHB-104 is an investigational new drug to treat Crohn's disease. RHB-204 is a treatment for pulmonary nontuberculous mycobacteria infections caused by MAC.

21 YEAR PERFORMANCE RESULTS

REDIF Dividend History Detail
REDIF Dividend News
REDIF Competitors News

# of Shares: 0

Closing Price: 0.67

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000